Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Anti-Cancer Drugs
|
March 13, 2015
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network
Roberta Sanfilippo, Palma Dileo, Jean-Yves Blay, et al.
Clinical Sarcoma Research
|
April 24, 2015
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
Attila Kollàr, Marco Maruzzo, Christina Messiou, et al.
British Journal of Cancer
|
November 16, 2024
UK guidelines for the management of bone sarcomas
Craig Gerrand, Fernanda Amary, Hanny A Anwar, et al.
Clinical Sarcoma Research
|
May 12, 2020
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
Spyridon Gennatas, Florence Chamberlain, Thomas Carter, et al.
Clinical Sarcoma Research
|
April 19, 2013
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
Bruno Vincenzi, Anna Maria Frezza, Gaia Schiavon, et al.
Cancers
|
August 23, 2020
Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic
Eugenie Younger, Alannah Smrke, Emma Lidington, et al.
EJNMMI Research
|
January 14, 2021
The role of [<sup>68</sup> Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST)
Luigi Aloj, Olivier Giger, Iosif A Mendichovszky, et al.
Nature Communications
|
March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2020
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
Patrick Schöffski, Olivier Mir, Bernd Kasper, et al.
The Lancet. Oncology
|
June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso, Robin L Jones, George D Demetri, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Anti-Cancer Drugs
|
March 13, 2015
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network
Roberta Sanfilippo, Palma Dileo, Jean-Yves Blay, et al.
Clinical Sarcoma Research
|
April 24, 2015
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program
Attila Kollàr, Marco Maruzzo, Christina Messiou, et al.
British Journal of Cancer
|
November 16, 2024
UK guidelines for the management of bone sarcomas
Craig Gerrand, Fernanda Amary, Hanny A Anwar, et al.
Clinical Sarcoma Research
|
May 12, 2020
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
Spyridon Gennatas, Florence Chamberlain, Thomas Carter, et al.
Clinical Sarcoma Research
|
April 19, 2013
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
Bruno Vincenzi, Anna Maria Frezza, Gaia Schiavon, et al.
Cancers
|
August 23, 2020
Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic
Eugenie Younger, Alannah Smrke, Emma Lidington, et al.
EJNMMI Research
|
January 14, 2021
The role of [<sup>68</sup> Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST)
Luigi Aloj, Olivier Giger, Iosif A Mendichovszky, et al.
Nature Communications
|
March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2020
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'
Patrick Schöffski, Olivier Mir, Bernd Kasper, et al.
The Lancet. Oncology
|
June 26, 2007
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso, Robin L Jones, George D Demetri, et al.
Page
of 4